Showing results (41-50 of 79) with videos related to

Sort By:
Pageof 8
The Oncologist|April 17, 2020
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual DiseaseSahra Ali, Alexandre Moreau, Daniela Melchiorri, et al.
Haematologica|June 30, 2011
The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Gonzalo Calvo, Ian Hudson, et al.
Clinical Pharmacology and Therapeutics|October 16, 2020
Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor MythHans-Georg Eichler, Francesco Pignatti, Brigitte Schwarzer-Daum, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2023
Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task ForceTommi Tervonen, Jorien Veldwijk, Katherine Payne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Jeanett Borregaard, Jens Ersbøll, et al.
The Oncologist|November 12, 2020
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple MyelomaKyriaki Tzogani, Karri Penttilä, Johanna Lähteenvuo, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
The Oncologist|October 29, 2017
Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple MyelomaDouwe Postmus, Sarah Richard, Nathalie Bere, et al.
Frontiers in Medicine|October 31, 2025
A model structure for describing uncertainties in benefit-risk assessment of oncology drug applicationsNikolaos Zafiropoulos, Francesco Pignatti, Andreas Kouroumalis, et al.
The Oncologist|December 2, 2017
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple MyelomaKyriaki Tzogani, Paula van Hennik, Ita Walsh, et al.
Pageof 8